Idec (NASDAQ: BIIB) announced it has submitted a Biologics License
Application (BLA) to the U.S. Food and Drug Administration (FDA) for
approval of PLEGRIDY™ (peginterferon beta-1a), the company's pegylated
Shares of XenoPort skidded lower this morning after the biotech announced its lead experimental drug had decisively failed a late-stage study for spasticity triggered by multiple sclerosis. The troubled biopharma company, which has been struggling...
XenoPort (Nasdaq: XNPT) announced today top-line results from its
pivotal Phase 3 clinical trial of arbaclofen placarbil (AP) for the
treatment of patients with spasticity due to multiple sclerosis (MS). The
trial was unsuccessful in demonstrating...
(MedPage Today) -- Patients with clinically isolated syndrome were significantly less likely to progress to definite multiple sclerosis after receiving the oral drug teriflunomide (Aubagio), its manufacturer said.
(MedPage Today) -- Progression from clinically isolated syndrome to definite multiple sclerosis was significantly associated with atrophy in the thalamus among patients treated with interferon-beta-1a, researchers said.
(MedPage Today) -- Several new medications for multiple sclerosis are in the short-term pipeline, and other treatments, including cell therapies, are on the more distant horizon, according to a well-known MS researcher.
Ampyra, a pill approved to help patients with multiple sclerosis walk, has put Acorda Therapeutics in the small club of profitable biotechnology companies. The drug generated $266 million in annual sales last year, helping Acorda generate a net...
(MedPage Today) -- Fetal defects in thymic function and inadequate circulating levels of vitamin D may explain the well recognized influence of birth month on risk for multiple sclerosis, British researchers suggested.
Omeros Corporation (NASDAQ: OMER) today announced positive data in the most commonly used model for studying the clinical and pathological features of multiple sclerosis (MS), further advancing its development program of GPR17-targeting compounds...
Oops! Unable to complete your request. Please refresh your browser.